Shares of Aurobindo Pharma Ltd slump 2% on 14 August after the US Food and Drug Administration (US FDA) issued a Warning Letter to Eugia Pharma Specialities’ Unit I, adding to regulatory concerns around the company’s injectable manufacturing business.

The facility is located in Hyderabad’s Pashamylaram area and supplies pharmaceutical products to regulated markets. The warning letter follows an earlier US FDA inspection of the facility. A warning letter is issued when the regulator finds significant violations that need corrective action. It can create additional scrutiny for the company’s products and future approvals from the affected facility.

The development is important because Eugia Pharma Specialities is Aurobindo Pharma’s key injectable business. The company operates several facilities under Eugia, supplying products to markets including the US.

The latest action also adds to the regulatory challenges faced by Aurobindo’s Eugia business. In June 2026, Eugia Unit III received an OAI, or Official Action Indicated, classification after an inspection that resulted in 11 observations. OAI is a serious regulatory classification and can affect the approval of products from the concerned facility.

The Unit III facility had also received a US FDA warning letter in August 2024 following an inspection earlier that year. The FDA said the facility had significant violations of current Good Manufacturing Practice requirements.

For investors, the latest warning letter increases the focus on Aurobindo’s ability to resolve compliance issues across its manufacturing network. The company has previously stated that it remains committed to maintaining quality standards and addressing regulatory observations.

Aurobindo’s diversified manufacturing base means the development does not necessarily affect its entire US business. However, repeated regulatory action at Eugia facilities could put pressure on the company’s injectable product pipeline and require additional spending on remediation.

At 10:15 am, the shares of Aurobindo Pharma were trading 2.12% lower at Rs 1,628 on the NSE.

The future of investing is here!
Tradz by EquityPandit leverages advanced AI technology to provide you with powerful market predictions and actionable stock scans. Download the app todayand 10x your trading & investing journey!